(Q37465049)

20 August 2017

1 reference

title

The anti-interleukin-1 in type 1 diabetes action trial--background and rationale (English)

1 reference

20 August 2017

0 references

0 references

Thomas Mandrup-Poulsen

object named as

Thomas R Mandrup-Poulsen

series ordinal

2

0 references

author name string

Linda M S Pickersgill

series ordinal

1

1 reference

20 August 2017

publication date

1 May 2009

1 reference

Diabetes - Metabolism: Research and Reviews

20 August 2017

published in

1 reference

20 August 2017

volume

25

1 reference

20 August 2017

issue

4

1 reference

20 August 2017

page(s)

321-324

1 reference

The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy

20 August 2017

cites work

1 reference

7 January 2021

The role of interleukin-1 in disease

1 reference

7 January 2021

The many worlds of reducing interleukin-1

1 reference

7 January 2021

Soluble interleukin-1 receptor accessory protein ameliorates collagen-induced arthritis by a different mode of action from that of interleukin-1 receptor antagonist.

1 reference

7 January 2021

Interleukin-1-receptor antagonist in type 2 diabetes mellitus

1 reference

7 January 2021

Safety of extended treatment with anakinra in patients with rheumatoid arthritis

1 reference

7 January 2021

The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions

1 reference

7 January 2021

Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans

1 reference

7 January 2021

Affinity-purified human interleukin I is cytotoxic to isolated islets of Langerhans

1 reference

7 January 2021

beta-Cell death during progression to diabetes

1 reference

7 January 2021

A choice of death--the signal-transduction of immune-mediated beta-cell apoptosis

1 reference

7 January 2021

Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade

1 reference

7 January 2021

Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra

1 reference

7 January 2021

Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor

1 reference

7 January 2021

Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled

1 reference

7 January 2021

C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001.

1 reference

7 January 2021

Identifiers

DOI

10.1002/DMRR.960

1 reference

20 August 2017

1 reference